|Bid||143.76 x 100|
|Ask||144.65 x 200|
|Day's Range||142.80 - 144.45|
|52 Week Range||96.93 - 144.45|
|PE Ratio (TTM)||44.67|
|Earnings Date||Oct 25, 2017 - Oct 30, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||153.48|
Juno Therapeutics Inc (NASDAQ:JUNO) is poised to benefit from a rising acquisition trend. Three weeks ago when Gilead Sciences, Inc. (NASDAQ:GILD) announced it would be acquiring smaller rival biopharma name Kite Pharma Inc (NASDAQ:KITE), traders clearly took notice. If Gilead wanted Kite for its CAR-T cancer therapy and Novartis AG (ADR) (NYSE:NVS) recently won the first-ever FDA approval for its CAR-T based oncology drug, there had to be something to it.
With the market grinding higher, some breakouts struggle. But Apple, Microsoft, Biogen, Alexion Pharmaceuticals, Wynn Resorts and Electronic Arts are holding in buy zones after breaking out several days or weeks ago.
Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.
Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”
Last month, Gilead Sciences (GILD) made big news when it announced the acquisition of Kite Pharma (KITE). For the most part, analysts were bullish on the deal, with the noted exception being Leerink's Geoffrey Porges and Bradley Canino. The pair penned a note late last month explaining why they were not excited by Gilead’s latest purchase.
|Initiated||RBC Capital : to Top Pick||9/15/2017|
|+ Upgrade||Argus : Hold to Buy||7/31/2017|
|Downgrade||BTIG Research : to Neutral||6/30/2017|
|+ Upgrade||Leerink Swann : to Outperform||6/16/2017|
|Downgrade||Argus Research : to Hold||5/5/2017|
|Initiated||Oppenheimer : to Outperform||11/29/2016|
Industry : Biotechnology
Full Time Employees : 7,132
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The companys products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.